Agilent Technologies - Utilizing Fast HPLC Screening Methods for the Detection of Steroids
As the importance of steroids in the regulation of bioprocesses has increased so has the demand for fast screening methods for their detection. HPLC is a highly regarded analytical technique for pharmaceutical applications due to its unrivalled analytical validation characteristics; including accuracy, precision, limit of detection, specificity, linearity and range, and ruggedness.
The high throughput demands of quantitative steroid analysis require faster run times and as a result there has been a focus on the development of fast HPLC screening methods to detect steroids such as hydrocortisone, testosterone and progesterone. Recent developments in HPLC column technology, such as sub-2 μm totally porous and sub-3 μm superficially porous columns, have offered improvements in separation speed and performance through reduced analysis times and increased separation efficiency. It is these improvements in column technology which mean that fast HPLC screening for the detection of steroids can be achieved.
Selectivity is the most powerful tool to optimize separations in HPLC and can be manipulated to improve separations. As a result, the analysis of steroids can be dramatically improved by choosing the optimal HPLC column for the separation. Selectivity can be increased by changing the mobile phase composition, column temperature and the composition of stationary phase; for example, the short column length and high efficiency of Poroshell 120 HPLC columns provide fast HPLC analysis times and rapid equilibration leading to fast investigations of selectivity.
A key feature of Poroshell 120 columns is their superficially porous microparticulate column packing. Poroshell 120 particles have a 1.7 μm solid silica core with a 0.5 μm porous outer layer. This unique configuration delivers all the performance advantages of sub-2 μm particles with the backpressure of a sub-3 μm particle. With Poroshell 120 columns, it is possible to achieve 80–90% or more of the efficiency expected from a sub-2 μm Fast LC/UHPLC column — but at HPLC pressures (below 400 bar). This ability to perform fast separations at low pressures can dramatically enhance productivity by allowing more samples to be run in less time — even using existing HPLC systems. This allows laboratories to generate better chromatographic results quicker so they can increase their throughput of samples.
To read the full story and discover how you can achieve fast HPLC screening methods click here.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.